A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label clinical study with separate Dose Escalation and Expansion
Phases to assess preliminary safety, tolerability, and efficacy of ATG-019, a dual inhibitor
of PAK4 and NAMPT, alone or co-administered with starting dose of 500 mg niacin ER in
patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).